Familiarisation visit for adults with chronic lung conditions before future trials
Adults with long-term lung conditions visit a trials unit for routine health checks.
Key facts
- Who runs it
- Richmond Research Institute
- Where
- London, United KingdomSee the site
- Trial code
- Registry title
- Chronic Respiratory Disease Participant Engagement Study
- Status
- Recruiting
- People taking part
- 500 people, planned
- Started
- Nov 2026
- Expected to end
- 1 Aug 2027
- Type of study
- Observational
- Record updated
- 9 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who have, or may have, a long-term lung condition such as AATD, COPD, asthma, bronchiectasis or ILD. It involves one visit to the clinical trials unit with routine health checks.
- Age
- 18 years or older
- Sex
- Women and men can both join
- Disease stage
- A diagnosed or suspected long-term lung disease, such as AATD, COPD, asthma, bronchiectasis, ILD or another chronic lung disease accepted by the Investigator and Sponsor
Main reasons for not taking part
- Not willing or not able to follow the study assessments
- Another significant disease that could put the person at risk or affect the clinical baseline, in the opinion of the Principal Investigator or Sponsor
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Male or female participants aged ≥ 18 years at the date of signing the PIS/ICF
- Ability to provide written, personally signed, and dated informed consent in accordance with International Council for Harmonisation (ICH) Good Clinical Practice (GCP) Guidelines E6 (R3) (2025) and applicable regulations, before any study-specific procedures are performed
- Diagnosis with or suspicion of chronic respiratory disease including but not limited to: AATD, COPD, Asthma, Bronchiectasis, ILD and any other chronic respiratory diseases considered appropriate by the Investigator and Sponsor
Who cannot take part
- Any other significant disease or disorder that, in the opinion of the Principal Investigator (PI) or Sponsor, may either place the participant at risk from participation, or influence the clinical baseline
- Unwilling or unable to comply with the protocol-defined study assessments
Where in United Kingdom
- Richmond Pharmacology LimitedLondon, United KingdomContact: Volunteer recruitmentTaking people
About the trial
What the trial wants to find out
This study is designed for adults who have, or suspected to have, a long-term respiratory (lung) condition such as Alpha-1 Antitrypsin Deficiency (AATD), chronic obstructive pulmonary disease (COPD), asthma, bronchiectasis, or interstitial lung disease (ILD).
Read full original descriptionShow less
The aim of the study is to help participants become familiar with the clinical trials unit environment and research team before deciding whether they would like to take part in future clinical trials.
Participants will attend a study visit at the clinical trials unit, where they will receive a guided tour of the facilities and undergo a range of routine health assessments. These may include a review of their medical history, measurements of height, weight, blood pressure and oxygen levels, breathing tests, blood tests, heart tracing (ECG), liver assessment, and questionnaires about their symptoms and quality of life. Some participants may also undergo genetic testing if it is clinically appropriate and previous results are not available.
The information collected will help establish a clinical baseline and improve understanding of how respiratory diseases affect people in everyday life. The study will also explore how symptoms and quality of life relate to clinical measurements and other health information.
Participants will be contacted after their visit to discuss any clinically relevant findings and to answer any questions they may have. If a previously unrecognised condition is identified, participants will be advised appropriately and, with their consent, their GP may be informed to support any further care that may be needed.
The findings from this study may help improve the design of future clinical trials and support the development of more patient-centred research.
The group in the trial
- Group 1
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Engagement Study to Establish a Clinical Baseline for Adult Participants With Chronic Respiratory Diseases and Familiarise Them With the Clinical Trials Unit Environment for Future Clinical Trial Participation
- Plain-language title
- Familiarisation visit for adults with chronic lung conditions before future trialsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 9 November 2026